Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DULOXETINE

All products: general benefit

Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable

  • Mirtazapine (Remeron RD): general benefit, Not a benefit
  • Trazodone (Desyrel): general benefit, Not a benefit
  • Venlafaxine (Effexor XR): general benefit
  • Vortioxetine (Trintellix): general benefit
  • Bupropion (Wellbutrin XL): limited Use 315, Not a benefit
  • Desvenlafaxine (Pristiq): not a benefit

17 more in the class list below

Accel-Duloxetine · DIN 02522861 · 30mg · DR capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accel-Duloxetine · DIN 02522861 Manufacturer: Accel Pharma Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-04-04 · brand ACCEL-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Accel pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Accel-Duloxetine: Formulary list price $0.3611/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3611 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101196 · Verify on the e-Formulary ↗ (DIN 02522861)

Source record
DIN 02522861: Accel-Duloxetine Raw flags: sec3=Y Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id ACC Source form: DR Cap; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.3611; ministry $0.3611 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522861 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101196
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611 Apo-Duloxetine · DIN 02440423 · $0.3611 Auro-Duloxetine · DIN 02436647 · $0.3611 Cymbalta · DIN 02301482 · not recorded Duloxetine · DIN 02453630 · $0.3611 Duloxetine · DIN 02490889 · $0.3611 Duloxetine DR · DIN 02437082 · $0.3611 Jamp Duloxetine Capsules · DIN 02512505 · $0.3611 Jamp-Duloxetine · DIN 02451913 · $0.3611 M-Duloxetine · DIN 02473208 · $0.3611 Mar-Duloxetine · DIN 02446081 · $0.3611 Mint-Duloxetine · DIN 02438984 · $0.3611 NRA-Duloxetine · DIN 02482126 · $0.3611 PMS-Duloxetine · DIN 02429446 · $0.3611 Ran-Duloxetine · DIN 02438259 · $0.3611 Sandoz Duloxetine · DIN 02439948 · $0.3611 Taro-Duloxetine · DIN 02457199 · $0.3611 Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab

TRAZODONE HYDROCHLORIDE

· 17 products · Listed, not a benefit (3), General benefit (14) · strengths: 50mg, 100mg, 150mg · Tab

VENLAFAXINE HCL

· 45 products · General benefit · strengths: 37.5mg, 75mg, 150mg · ER Cap

VORTIOXETINE HYDROBROMIDE

· 6 products · General benefit · strengths: 5mg, 10mg, 20mg · Tab

BUPROPION HCL

· 12 products · Limited Use, codes 315 (10), Listed, not a benefit (2) · strengths: 150mg, 300mg, 100mg · ER Tab, Tab

DESVENLAFAXINE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 100mg · ER Tab

VILAZODONE HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg, 40mg · Tab

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: anxiety disorder, major depressive disorder, pain associated with fibromyalgia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BREXPIPRAZOLE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE ALPRAZOLAM · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) Generalized Anxiety Disorder XANAX and XANAX TS are indicated for the treatment of Generalized Anxiety Disorder (GAD). PM: https://pdf.hres.ca/dpd_pm/00070545.PDF; date not captured; DIN 00548359; fetched 2026-09-10 Product monograph BREXPIPRAZOLE · General benefit • use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients with an inadequate response to prior antidepressant treatments during the current episode (see 14.1 Clinical Trials by Indication, Adjunctive Treatment in Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00074327.PDF; date February 16, 2017; DIN 02461749; fetched 2026-09-10 Product monograph DESVENLAFAXINE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS PRISTIQ (desvenlafaxine succinate) is indicated for: • symptomatic relief of major depressive disorder in adults. PM: https://pdf.hres.ca/dpd_pm/00074568.PDF; date FEB 04, 2009; DIN 02321092; fetched 2026-09-10 Product monograph FLUOXETINE HCL · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) 1 INDICATIONS pms-FLUOXETINE (fluoxetine) is indicated in adults for: • Depression: pms-FLUOXETINE is indicated for the symptomatic relief of Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00076968.PDF; date AUG 30, 2024; DIN 02177579; fetched 2026-09-10 Product monograph PREGABALIN · General benefit (93), Off-Formulary Interchangeable, not an ODB benefit (9) 1 INDICATIONS Adults LYRICA (pregabalin capsules) is indicated for the management of neuropathic pain associated with: • Diabetic peripheral neuropathy; • Postherpetic neuralgia; • Spinal cord injury LYRICA is indicated for the management of pain associated with fibromyalgia. PM: https://pdf.hres.ca/dpd_pm/00074814.PDF; date MAR 4, 2024; DIN 02268418; fetched 2026-09-10 Product monograph VENLAFAXINE HCL · General benefit 1 INDICATIONS EFFEXOR XR (venlafaxine hydrochloride extended release capsules) is indicated for the symptomatic relief of: • Major depressive disorder • Anxiety causing clinically significant distress in patients with generalized anxiety disorder (GAD). PM: https://pdf.hres.ca/dpd_pm/00073109.PDF; date AUG 09, 2023; DIN 02237279; fetched 2026-09-10 Product monograph VILAZODONE HYDROCHLORIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VIIBRYD (vilazodone hydrochloride tablets) is indicated for the symptomatic relief of Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00073801.PDF; date JUL 15, 2015; DIN 02443724; fetched 2026-09-10 Product monograph VORTIOXETINE HYDROBROMIDE · General benefit 1 Indications TRINTELLIX (vortioxetine hydrobromide) is indicated for: • the treatment of major depressive disorder (MDD) in adults. PM: https://pdf.hres.ca/dpd_pm/00085298.PDF; date 2026-07-10; DIN 02432919; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 Indications pms-DULOXETINE (Duloxetine Delayed-Release Capsules) is indicated in adults for: • Major Depressive Disorder pms-DULOXETINE is indicated for the symptomatic relief of major depressive disorder (MDD). The efficacy of duloxetine hydrochloride in maintaining an antidepressant response for up to 12 months in patients who have shown initial treatment response following up to 34 weeks of open-label acute treatment was demonstrated in 2 placebo-controlled trials. The efficacy of duloxetine hydrochloride in hospitalized patients with MDD has not been studied. • Generalized Anxiety Disorder pms-DULOXETINE is indicated for the symptomatic relief of anxiety causing clinically significant distress in patients with generalized anxiety disorder (GAD). The efficacy of duloxetine hydrochloride in maintaining anxiolytic response for up to 6 months in patients with GAD was demonstrated in a long-term placebo-controlled trial in patients who had initially responded to duloxetine hydrochloride during a 6-month open- label phase. • Neuropathic Pain Associated with Diabetic Peripheral Neuropathy pms-DULOXETINE is indicated for the management of ne… https://pdf.hres.ca/dpd_pm/00084896.PDF PM date: 2026-05-29 Source product: PMS-DULOXETINE; DIN 02429446; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.